Physician profile
Ghazal Kango
NPI 1306370770
$1,149.82
in general payments reported to CMS, 2019-2025
22 companies · $248 in 2025
The $248 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $513 · 2023: $157 · 2024: $232 · 2025: $248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $637.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $636.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $269.69 | 2022 | |
| Gilead Sciences, INC. | $172.59 | 2023-2025 | Trodelvy |
| Abbvie INC. | $125.00 | 2022 | |
| Genzyme Corporation | $118.34 | 2022 | |
| Aveo Pharmaceuticals, INC. | $52.10 | 2024-2025 | |
| Puma Biotechnology, INC. | $46.51 | 2024-2025 | |
| Novocure INC. | $44.21 | 2025 | Optune Lua (Novottf-200t) |
| Astrazeneca Pharmaceuticals LP | $37.35 | 2024-2025 | Calquence |
| Apellis Pharmaceuticals, INC. | $34.56 | 2024 | Empaveli |
| Adaptive Biotechnologies Corporation | $26.85 | 2024 | Clonoseq |
| Taiho Oncology, INC. | $23.38 | 2025 | |
| Myriad Genetic Laboratories, INC. | $22.63 | 2025 | Myrisk |
| Array Biopharma INC | $21.80 | 2024 | Braftovi, Tukysa, Mektovi |
| Ipsen Biopharmaceuticals, INC | $18.80 | 2025 | Onivyde |
| Janssen Biotech, INC. | $17.94 | 2024 | Tecvayli, Talvey, Darzalex |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $17.92 | 2024 | Provenge |
| Stemline Therapeutics INC. | $17.56 | 2025 | Orserdu |
| Celgene Corporation | $17.19 | 2024 | Reblozyl |
| Amneal Pharmaceuticals LLC | $17.01 | 2025 | Alymsys |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.58 | 2025 | |
| Novartis Pharmaceuticals Corporation | $15.96 | 2024 | |
| Glaxosmithkline, LLC. | $15.85 | 2025 | Zejula, Jemperli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ghazal Kango listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.